Impact of Prolonged Exacerbation Recovery in Chronic Obstructive Pulmonary Disease.

RATIONALE Exacerbations are important and heterogeneous events in the natural history of chronic obstructive pulmonary disease (COPD). OBJECTIVES To examine the consequences of prolonged exacerbation recovery in patients with COPD. METHODS A cohort of 384 patients with COPD (FEV1 % predicted 45.8 [SD, 16.6] and a median exacerbation rate of 2.13 per year [interquartile range, 1.0-3.2]) were followed for 1,039 days (interquartile range, 660-1,814) between October 1995 and January 2013. Patients recorded daily worsening of respiratory symptoms and peak expiratory flow (PEF), and when stable underwent spirometry every 3 months, and completed the St. George's Respiratory Questionnaire annually. Exacerbations were diagnosed as 2 consecutive days with one major symptom plus another respiratory symptom. Exacerbation duration was defined as the time from onset to the day preceding 2 consecutive symptom-free days and recovery in PEF as return to preexacerbation levels. MEASUREMENTS AND MAIN RESULTS A total of 351 patients had one or more exacerbations. Patients with a longer symptom duration (mean, 14.5 d) had a worse St. George's Respiratory Questionnaire total score (0.2 units per 1 day; P = 0.040). A longer symptomatic duration was associated with a shorter interval between exacerbation recovery and onset of the next exacerbation (hazard ratio, 1.004; P = 0.013). For 257 (7.3%) exacerbations, PEF did not recover within 99 days. These exacerbations were associated with symptoms of a viral infection (cold and sore throat). Patients with these nonrecovered exacerbations showed a 10.8 ml/yr (P < 0.001) faster decline in FEV1. CONCLUSIONS Prolonged exacerbation symptomatic duration is associated with poorer health status and a greater risk of a new event. Exacerbations where lung function does not recover are associated with symptoms of viral infections and accelerated decline in FEV1.

[1]  G. Donaldson,et al.  M23 COPD exacerbations of longer duration worsens health related quality of life , 2013, Thorax.

[2]  John R Hurst,et al.  Factors associated with change in exacerbation frequency in COPD , 2013, Respiratory Research.

[3]  J. Wedzicha,et al.  Changes in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPD , 2012, Thorax.

[4]  S. Suissa,et al.  Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality , 2012, Thorax.

[5]  A. Anzueto,et al.  Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results , 2011, European Respiratory Journal.

[6]  J. Wedzicha,et al.  Temporal clustering of exacerbations in chronic obstructive pulmonary disease. , 2010, American journal of respiratory and critical care medicine.

[7]  F. Schellevis,et al.  Reduced risk of next exacerbation and mortality associated with antibiotic use in COPD , 2008, European Respiratory Journal.

[8]  Lei Liu,et al.  A Joint Frailty Model for Survival and Gap Times Between Recurrent Events , 2007, Biometrics.

[9]  T. Seemungal,et al.  Airway and Systemic Inflammation and Decline in Lung Function in Patients With COPD , 2005, Chest.

[10]  Carl van Walraven,et al.  Time-dependent bias was common in survival analyses published in leading clinical journals. , 2004, Journal of clinical epidemiology.

[11]  P. Sagnier,et al.  Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. , 2004, Chest.

[12]  I. Stiell,et al.  Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. , 2003, The New England journal of medicine.

[13]  T. Seemungal,et al.  Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease , 2002, Thorax.

[14]  T. Seemungal,et al.  Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. , 2001, American journal of respiratory and critical care medicine.

[15]  T. Seemungal,et al.  Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. , 2000, American journal of respiratory and critical care medicine.

[16]  T. Seemungal,et al.  Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations , 2000, Thorax.

[17]  D. Niewoehner,et al.  Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. , 1999, The New England journal of medicine.

[18]  T. Seemungal,et al.  Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. , 1998, American journal of respiratory and critical care medicine.

[19]  P. Jones,et al.  A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. , 1992, The American review of respiratory disease.